Ibrutinib dose intensity in high‐risk chronic lymphocytic leukemiaGabriela Forestieri, Adalgisa Condoluci, Annagiulia Zanatta et al.|Hematological Oncology|2022Cited by 2
S225: CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER AT BASELINE AND IMPROVES THE ACCURACY OF INTERIM PET IN CLASSIC HODGKIN LYMPHOMAMaria Cristina Pirosa, Davide Rossi, Alessio Bruscaggin et al.|HemaSphere|2022Cited by 1
Poster: HL-370 Fragmentome Profiling Reveals Distinct Molecular Subgroups of Classic Hodgkin LymphomaLodovico Terzi di Bergamo, Davide Rossi, Maria Cristina Pirosa et al.|Clinical Lymphoma Myeloma & Leukemia|2022Cited by 0
Clinical utility of circulating tumor DNA qualification and quantification in classical Hodgkin lymphomaMaria Cristina Pirosa, Davide Rossi, Alessio Bruscaggin et al.|Hematological Oncology|2023Cited by 0
Clonal Hematopoiesis in Diffuse Large B-Cell Lymphoma: Clinical and Molecular CorrelationsIlaria Romano, Davide Rossi, Joyce Marques de Almeida et al.|Blood|2024Cited by 0